ESR1 and breast cancer: (16) reported the area under the concentration-time curve (AUC) of E2 following treatment with a 3-month 10.8-mg depot of goserelin (n = 86) and a monthly 3.6-mg dose (n = 84) in premenopausal patients with estrogen receptor-positive breast cancer.